HYML-122
Tier C — Watch / tradeHYML-122
Targets：FLT3
Indications (approved)：Acute myeloid leukaemia
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| HYML-122-001 | 2380-63-4Available | 1H-pyrazolo[3,4-d]pyrimidin-4-amine |
| HYML-122-002 | 151266-23-8Available | 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine |
| HYML-122-003 | 51067-38-0 | (4-phenoxyphenyl)boronic acid |
| HYML-122-004 | 330786-24-8Available | 3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine |
| HYML-122-005 | 143900-44-1Available | tert-butyl (S)-3-hydroxypiperidine-1-carboxylate |
| HYML-122-006 | 1022150-12-4Available | (R)-3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine |
| HYML-122-007 | 1118-68-9 | dimethylglycine |
| HYML-122 | 1839150-56-9 | Ethanone, 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-(dimethylamino)- |
Frequently asked questions
What are the approved indications of HYML-122?
Approved indications include: Acute myeloid leukaemia.
When does the HYML-122 patent expire?
No public expiry year is available for HYML-122 yet; this page updates once verified.
How many synthesis routes are recorded for HYML-122?
1 synthesis routes are recorded; the shortest is 4 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy HYML-122 intermediates?
5 intermediate CAS of HYML-122 are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for HYML-122 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06